

PHARMACY POLICY STATEMENT

North Carolina Marketplace

DRUG NAME	Yutiq (fluocinolone acetonide)
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Yutiq is a 0.18 mg fluocinolone acetonide intravitreal implant that was approved by the FDA in 2018. It is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye and lasts 36 months.

Uveitis is an inflammation of the uvea (middle layer of the eye). It can be infectious or non-infectious. Non-infectious uveitis (NIU) is often associated with inflammatory conditions such as rheumatoid arthritis. If the anterior segment of the uvea is affected, it can be treated with topical glucocorticoids. If resistant or affecting the intermediate or posterior segments, more invasive or systemic treatment is needed.

Yutiq (fluocinolone acetonide) will be considered for coverage when the following criteria are met:

Uveitis

CareSource considers Yutiq (fluocinolone acetonide) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
11/02/2021	New policy created for Yutiq.
10/18/2023	Updated references.

References:

- 1.